Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicament used for treating breast cancer

A combined drug and breast cancer technology, which is applied in the field of breast cancer treatment, can solve the problems of TNBC patients with no curative effect, and achieve the effect of enhancing anti-tumor immunity, good safety, and inhibiting growth

Inactive Publication Date: 2021-03-19
HUAZHONG AGRI UNIV +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drugs such as trastuzumab and tamoxifen are effective in breast cancer patients with Her-2 and ER overexpression, but not in TNBC patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicament used for treating breast cancer
  • Combined medicament used for treating breast cancer
  • Combined medicament used for treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 BCG activates anti-tumor immunity

[0029] 1. Construction of a mouse model of orthotopic triple-negative breast cancer

[0030] Inject 1×10 in the right fourth pair of mammary fat pads of 8-week-old female Balb / c mice 6 4T1-luc cells were used to construct an orthotopic breast cancer mouse model.

[0031] 2. BCG increases the number of tumor lymphocytes

[0032] To analyze the effect of BCG treatment on tumor-infiltrating lymphocytes, mice were injected intratumorally with 10 μl OD on day 5 after tumor inoculation. 600 =2 BCG contained in PBS, 9 days after BCG inoculation, the mice were anesthetized and sacrificed, and the tumor mass was isolated. Separate the tumor from the surrounding fascia with sterile scissors and triturate. Cell clumps were removed by passing through a 70 μm cell strainer to obtain a single cell suspension. Lymphocytes were isolated using the Mouse Tumor Infiltrating Tissue Lymphocyte Isolation Kit (Solarbio). Wash twice with PBS ...

Embodiment 2 3

[0037] Example 2 Three doses of BCG in the treatment of triple negative breast cancer

[0038] 1. Construction of a mouse model of orthotopic triple-negative breast cancer

[0039] Inject 1×10 in the right fourth pair of mammary fat pads of 8-week-old female Balb / c mice 64T1-luc cells were used to construct an orthotopic breast cancer mouse model.

[0040] 2. Three doses of BCG in the treatment of triple-negative breast cancer

[0041] To verify the oncolytic effect of BCG, animals were randomly divided into three groups on day 5 after tumor inoculation. In the single-dose BCG treatment group, one dose of BCG (1.5×10 6 CFU). In the three-dose BCG treatment group, one dose of BCG (1.5×10 6 CFU). In the PBS group, mice were injected with 10 microliters of PBS on days 5, 9 and 13 after tumor inoculation. Measure the long diameter (L) and short diameter (W) of the tumor mass with a vernier caliper every 2-3 days. According to the calculation formula of ellipsoid volume (ie...

Embodiment 3

[0043] Example 3 Combined treatment of BCG preparation and immunomodulator for triple-negative breast cancer

[0044] 1. Construction of a mouse model of orthotopic triple-negative breast cancer

[0045] Inject 1×10 in the right fourth pair of mammary fat pads of 8-week-old female Balb / c mice 6 4T1-luc cells were used to construct an orthotopic breast cancer mouse model.

[0046] 2. Combination of BCG preparations and immunomodulators in the treatment of triple-negative breast cancer

[0047] To verify the oncolytic effect of BCG and PD-L1 blocker (BMS202) combination therapy on TNBC mouse model, mice were randomly divided into four groups on day 5 after tumor inoculation. In the BCG combined with anti-PD-L1 treatment group, a dose of BCG (1.5×10 6 CFU), on the 9th day after BCG injection, intraperitoneally inject a dose of BMS202 (7 parts in total) plus a dose (10 microliters) of BMS202 (7 parts in total) to mice every day for 7 consecutive days. corn oil (7 servings tota...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a combined medicament used for treating the breast cancer. The combined medicament consists of an effective dose of BCG vaccine preparations, immunomodulators and pharmaceutically acceptable auxiliary materials. The combined medicament combines the BCG vaccine preparations and the immunomodulators, safety is good, in addition, expression of chemokine related genes and anti-tumor effect genes can be up-regulated, the expression of immunosuppression related genes can be down-regulated, an amount of tumor infiltrating lymphocytes is increased, and anti-tumor immunity is enhanced; and on an animal tumor model, growth of triple negative breast cancer tumors can be favorably restrained, and the combined medicament is better than any one independent medicine treatment method.

Description

technical field [0001] The invention relates to the field of treating breast cancer, in particular to a combined medicament for treating breast cancer. Background technique [0002] Breast cancer is a common female malignant tumor. In recent years, the incidence rate in my country has increased year by year, and it has become the female malignant tumor with the highest incidence rate in my country. Triple negative breast cancer (Triple Negative Breast Cancer, TNBC) is a subtype of breast cancer, which is characterized by high invasiveness, strong metastasis and poor prognosis. lowest five-year survival rate. TNBC specifically refers to breast cancer that lacks expression of estrogen receptor (Estrogen Receptor, ER), progesterone receptor (Progesterone Receptor, PR) and human epidermal growth factor receptor 2 (Humanepidermal growth factor receptor 2, Her-2). Drugs such as trastuzumab and tamoxifen are effective in breast cancer patients with overexpression of Her-2 and ER,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K39/04A61P35/00A61P15/14A61P37/04
CPCA61K45/06A61K39/04A61P35/00A61P15/14A61P37/04
Inventor 曹罡鲁愿何文波黄信刘小可何雨徐伟泽
Owner HUAZHONG AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com